MARC Record from Harvard University

LEADER: 02003cam a2200373uu 4500
001 000540425-8
005 20020606090541.3
008 840919m19851986dcu b 00100 eng
010 $a 84062037 //r862
020 $a0309034949 (pbk. : v. 1)
020 $a0309036798 (pbk. : v. 2)
035 0 $aocm11667096
040 $aDLC$cDLC
043 $an-us---$ad------
245 00 $aNew vaccine development :$bestablishing priorities.
260 0 $aWashington, D.C. :$bNational Academy Press,$c1985-1986.
300 $a2 v. ;$c28 cm.
500 $a"... a two-part study by the Committee on Issues and Priorities for New Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine."
500 $a"The work on which this publication is based was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract no. NO1-AI-22678"--P. [ii] (v. 1).
500 $aPrepared for the National Institute of Allergy and Infectious Diseases.
500 $aVol. 2 has statement of responsibility: by the Committee on Issues and Priorities for New Vaccine Development, Division of Health Promotion and Disease Prevention and Division of International Health, Institute of Medicine.
504 $aIncludes bibliographies and indexes.
505 0 $av. 1. Diseases of importance in the United States -- v. 2. Diseases of importance in developing countries.
650 0 $aCommunicable diseases$zDeveloping countries$xPreventive inoculation.
650 0 $aCommunicable diseases$zUnited States$xPreventive inoculation.
650 0 $aVaccines$xResearch$xGovernment policy.
650 2 $aHealth Planning
650 2 $aPublic Policy
650 2 $aVaccines$xsupply & distribution.
651 2 $aUnited States
710 2 $aInstitute of Medicine (U.S.).$bCommittee on Issues and Priorities for New Vaccine Development.
710 2 $aNational Institute of Allergy and Infectious Diseases (U.S.)
988 $a20110914
906 $0DLC